Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Alexi Anne Wright, M.D.

Co-Author

This page shows the publications co-authored by Alexi Wright and Ursula Matulonis.
Connection Strength

2.160
  1. Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecol Oncol. 2021 05; 161(2):581-586.
    View in: PubMed
    Score: 0.231
  2. Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer. Gynecol Oncol. 2021 02; 160(2):457-463.
    View in: PubMed
    Score: 0.227
  3. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794.
    View in: PubMed
    Score: 0.208
  4. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer. Am J Obstet Gynecol. 2019 12; 221(6):625.e1-625.e14.
    View in: PubMed
    Score: 0.205
  5. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol. 2019 07; 154(1):95-101.
    View in: PubMed
    Score: 0.204
  6. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016 11 10; 34(32):3854-3863.
    View in: PubMed
    Score: 0.171
  7. Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncol. 2016 Nov 01; 2(11):1427-1433.
    View in: PubMed
    Score: 0.171
  8. Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2015 Sep 10; 33(26):2841-7.
    View in: PubMed
    Score: 0.157
  9. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013 Nov 01; 119(21):3776-83.
    View in: PubMed
    Score: 0.137
  10. Influence of patients' preferences and treatment site on cancer patients' end-of-life care. Cancer. 2010 Oct 01; 116(19):4656-63.
    View in: PubMed
    Score: 0.112
  11. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. J Clin Oncol. 2010 Oct 10; 28(29):4457-64.
    View in: PubMed
    Score: 0.112
  12. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br J Cancer. 2022 Apr; 126(7):1027-1036.
    View in: PubMed
    Score: 0.061
  13. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 05 10; 39(14):1531-1539.
    View in: PubMed
    Score: 0.058
  14. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020 10; 159(1):72-78.
    View in: PubMed
    Score: 0.055
  15. Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol Rep. 2019 Aug; 29:118-122.
    View in: PubMed
    Score: 0.052
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.